163 related articles for article (PubMed ID: 38262897)
1. [Updates on immunotherapy of gastrointestinal cancers and practical challenges].
Chen F; Wang F; Xu RH
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jan; 27(1):24-34. PubMed ID: 38262897
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies.
Harrold EC; Keane F; Cercek A
Clin Adv Hematol Oncol; 2024 May; 22(4):162-173. PubMed ID: 38739719
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
Zhang JW; Deng YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy for microsatellite-instability-high advanced colorectal cancer].
Ding PR
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):199-204. PubMed ID: 35340168
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
9. Current status and prospect of immunotherapy for colorectal cancer.
Yang W; Zheng H; Lv W; Zhu Y
Int J Colorectal Dis; 2023 Nov; 38(1):266. PubMed ID: 37962772
[TBL] [Abstract][Full Text] [Related]
10. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability of Gastric and Colorectal Cancers as a Predictor of Synchronous Gastric or Colorectal Neoplasms.
Kim YB; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Han HS
Gut Liver; 2016 Mar; 10(2):220-7. PubMed ID: 26087787
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H
Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability-High Gastric Cancer: A Case Series.
Liu L; Woo Y; D'Apuzzo M; Melstrom L; Raoof M; Liang Y; Afkhami M; Hamilton SR; Chao J
J Natl Compr Canc Netw; 2022 Aug; 20(8):857-865. PubMed ID: 35948034
[TBL] [Abstract][Full Text] [Related]
14. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant immunotherapy for colorectal cancer].
Pei JP; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
[TBL] [Abstract][Full Text] [Related]
17.
Li L; Li M; Jiang Z; Wang X
Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal Cancers.
Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB
Oncology; 2023; 101(4):213-223. PubMed ID: 36626879
[TBL] [Abstract][Full Text] [Related]
19. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
20. Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy.
Gervaso L; Bottiglieri L; Meneses-Medina MI; Pellicori S; Biffi R; Fumagalli Romario U; De Pascale S; Sala I; Bagnardi V; Barberis M; Cella CA; Fazio N
Clin Transl Oncol; 2023 Nov; 25(11):3287-3295. PubMed ID: 37084152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
